Yuan Mingzhong's Ziqian Tongmai Tang Impact On Hcy?hs-CRP Of Patients With Essential Hypertension(Hyperactivity Syndrome)

Objective:By observing the clinical efficacy of the Yuan Mingzhong's Ziqian Tongmai Tang,use it to treat patients with essential hypertensionon of hyperactivity syndrome. Explore the reducing the mechanism of blood pressure and serum homocysteine(Hcy) and high-sensitivity C-reactive protein(hs-CRP),which for the treatment of essential hypertensionon of hyperactivity syndrome offers reliable clinical basis.Methods:From July 2014 to May 2015,choose 60 cases patients who were diagnosed essential hypertension(hyperactivity syndrome) and meet that are the criteria for diagnostic,inclusion and exclusion. 60 enrolled patients were randomly divided into the experimental group(30 cases) and the control group(30 cases).The two groups in gender, age, weight, body mass index, duration, traditional Chineses Medicine syndromes, Hcy, hs-CRP and other aspects were no significant difference(P<0.05).The control group received Benzenesulfonic Amlodipine Tablets(Shi Hui Da), the test group received the Yuan Mingzhong's Ziqian Tongmai Tang and Benzenesulfonic Amlodipine Tablets. Before and after the experiment,record and compare the changes between the two groups in the blood pressure, clinical symptoms, Hcy, hs-CRP aspects.Results:Reduce blood pressure: compared the total efficiency of the test group(90%) with the total efficiency of the control group(70%), which the difference was statistically significant(P <0.05), this results illustrated the test group is better than the control group.In Clinical efficacy aspect, compared the efficiency of the test group(90%) with the efficiency of the control group(53.33%),which the difference was statistically significant(P <0.05), this results illustrated the test group is better than the control group in improving clinical efficacy.In Hcy aspect, in reducing the Hcy levels,the test group compared to the control group,which was statistically difference(P <0.05).In hs-CRP aspect,compare the experimental group to the control group, the experimental group was better, with significant difference between them. In clinical application processing,have no found adverse reactions.Conclusion: In the treatment of patients with essential hypertension(hyperactivity syndrome), Yuan Mingzhong's Ziqian Tongmai Tang has improved clinical symptoms because it has clear clinical efficacy.for example,knee soft, backache,five upset hot, heart palpitations, tinnitus and other symptoms,and it can significantly reduce Hcy and hs-CRP levels.